Location of Repository

Ressonância magnética hepática com Gd-EOB-DTPA: diferenciação entre hiperplasia nodular focal e adenoma hepatocelular.

By Maria Antónia Portilha, Marcos Teixeira Pedro, Catarina Ruivo, Luís Curvo Semedo, Cristina Marques and Filipe Caseiro Alves

Abstract

Gadoxetic acid (Gd-EOB-DTPA) is a contrast media used in magnetic resonance imaging (MRI) for the detection and characterization of hepatic lesions. It shows combined properties of extracellular and biliary excretion, with 50% of the administered dose eliminated by the hepatobiliary pathway. One of its applications, therefore, is the characterization of focal hepatic lesions, including those of hepatocellular nature, such as focal nodular hyperplasia and hepatocellular adenoma. Patients with focal nodular hyperplasia (FNH) are usually asymptomatic and rarely reveal complications. In other hand, hepatocellular adenoma may suffer complications, such as intraperitoneal or intratumoral (sometimes massive) bleeding and the possible progression to malignancy.To determine the value of MRI with Gd-EOB-DTPA in characterizing hepatic lesions, particularly in the differentiation between HNF and AHC. Material and methods: A retrospective study was carried out by investigating cases of FNH and HCA referred for MR evaluation with Gd-EOB-DTPA in the Department of Radiology of the University Hospitals of Coimbra (HUC) between August 2009 and December 2010. We evaluated 32 patients, 24 with FNH and 8 AHC. The diagnosis was established by histology, follow-up or agreement between imaging methods. In order to evaluate the enhancement after contrast administration in the hepatobiliary phase, we calculated the values of Signal-to-noise ratio (SNR), Contrast-to-noise ratio (CNS) and percentage of enhancement. Statistical analysis was performed with SPSS, version 18, and the tests were evaluated at a significance level of 5%.The SNR and CNR after contrast is significantly different for the two types of lesion (pGadoxetic acid (Gd-EOB-DTPA) is a contrast media used in magnetic resonance imaging (MRI) for the detection and characterization of hepatic lesions. It shows combined properties of extracellular and biliary excretion, with 50% of the administered dose eliminated by the hepatobiliary pathway. One of its applications, therefore, is the characterization of focal hepatic lesions, including those of hepatocellular nature, such as focal nodular hyperplasia and hepatocellular adenoma. Patients with focal nodular hyperplasia (FNH) are usually asymptomatic and rarely reveal complications. In other hand, hepatocellular adenoma may suffer complications, such as intraperitoneal or intratumoral (sometimes massive) bleeding and the possible progression to malignancy.To determine the value of MRI with Gd-EOB-DTPA in characterizing hepatic lesions, particularly in the differentiation between HNF and AHC. Material and methods: A retrospective study was carried out by investigating cases of FNH and HCA referred for MR evaluation with Gd-EOB-DTPA in the Department of Radiology of the University Hospitals of Coimbra (HUC) between August 2009 and December 2010. We evaluated 32 patients, 24 with FNH and 8 AHC. The diagnosis was established by histology, follow-up or agreement between imaging methods. In order to evaluate the enhancement after contrast administration in the hepatobiliary phase, we calculated the values of Signal-to-noise ratio (SNR), Contrast-to-noise ratio (CNS) and percentage of enhancement. Statistical analysis was performed with SPSS, version 18, and the tests were evaluated at a significance level of 5%.The SNR and CNR after contrast is significantly different for the two types of lesion (

Publisher: Ordem dos Médicos
Year: 2011
OAI identifier: oai:ojs.www.actamedicaportuguesa.com:article/1439
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.rcaap.pt/detail.jsp... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.